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Abstract
Objective To evaluate the differences between adults who
consent to participate in observational research, and those who
do not.
Design Prospective, population based cohort study.
Setting Primary and secondary care throughout Scotland.
Participants 187 adults (aged ≥ 16 years) resident in Scotland
at the time of their first diagnosis of a brain arteriovenous
malformation in 1999-2002.
Intervention Postal consent form sent via participants’ general
practitioner.
Main outcome measures Differences between consenters and
non-consenters in demographic and clinical features at first
presentation, and outcome during follow-up.
Results 111 adults (59%) consented to participate in the study.
These consenters were not significantly different from
non-consenters in age, sex, or socioeconomic status at first
presentation. However, consenters were significantly more likely
than non-consenters to present alive and independent, and with
a seizure. During follow-up, consenters were significantly more
likely to receive interventional treatment. Although consenters’
survival was significantly better, they were more likely to have a
seizure during follow-up. Presentation with intracranial
haemorrhage conferred a higher risk of subsequent
haemorrhage when the whole cohort was analysed, but not
when it was restricted to consenters.
Conclusions We have found differences between adults who
consent to participate in observational records-based research
and those who do not, or cannot, consent. Blanket requirements
for explicit consent for the use of individuals’ identifiable data
can bias disease registers, epidemiological studies, and health
services research.
Introduction
Hitherto, the United Kingdom has nurtured extremely high
quality disease registers, epidemiological studies, and health
services research. These studies have been robust because they
have avoided bias by being representative of the entire
population or patient group. Often, identifiable data have been
required for essential purposes such as record linkage using sec-
ondary data sources, identification of individuals during
follow-up, and the avoidance of double counting. However, to
use such identifiable data in observational research, UK
researchers are now under pressure to obtain informed consent
from each and every individual. Because of the inconsistencies in
data protection law and confidentiality guidance in the UK,1 a
blanket requirement for consent has become the “default
position” for most regulatory bodies and doctors in primary and
secondary care.
Similar epidemiological research at the Mayo Clinic Founda-
tion, Rochester MN, United States, was threatened by national
privacy standards that were part of the 1996 Health Insurance
Portability and Accountability Act.2 In the US, however, a supple-
mentary privacy rule sanctioned the disclosure of information
without patients’ consent for public health use and medical
records research,3 whereas in the UK statutory regulations and
professional guidance continue to contradict each other.1
The UK Data Protection Act 1998 does not apply to the dead
and makes exemptions for some forms of medical research, but
the General Medical Council document Confidentiality: Protecting
and Providing Information (2004, page 3) states that doctors
should “seek patients’ express consent to disclosure of informa-
tion, where identifiable data [are] needed for any purpose other
than the provision of care or for clinical audit.” Furthermore, the
Health and Social Care Act 2001 has established a bureaucratic
framework for approving the use of identifiable data without
patients’ explicit consent, but it applies only to England and
Wales—not Scotland—and it is intended to be a temporary meas-
ure until such time as health data are anonymised. The
legislation in the two acts is supplemented by doctors’ duty of
confidentiality to their patients under common law. However,
what remains untested in a court of law is the overall balance
between the privacy interests of an individual and the public
interest of unbiased research.
One would anticipate that consent might be impossible to
obtain from those who are untraceable or deny their diagnosis,
and particular groups of patients who are often of the greatest
importance (such as those who have died, are cognitively
impaired, or have a comorbid mood disorder). Excluding such
patients because of their lack of consent is likely to bias observa-
tional research. This phenomenon has been variously termed
response, refusal, participation, or authorisation bias when
applied to surveys and medical records research,4 but, since lack
of consent is the root cause, we prefer to call it consent bias.
We have had a unique opportunity to examine the direction
and size of consent bias in a prospective, population based study
in which we could not obtain consent from every participant, yet
we had research ethics committee approval to collect baseline
and follow-up data on the whole cohort.
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Methods
Scottish intracranial vascular malformation study (SIVMS)
The Scottish intracranial vascular malformation study comprises
a cohort of adults resident in Scotland whose intracranial vascu-
lar malformation was first diagnosed on or after 1 January 1999.5
After each patient is notified to the study team, the team asks the
patient’s general practitioner and hospital consultant whether it
is appropriate to approach the patient with a postal consent
pack. If they deem sending a consent pack to be inappropriate
they are asked for a reason, and any differences of opinion are
resolved by correspondence. The team prepares the consent
pack, having checked the patient’s address, but sends the pack to
each patient via his or her general practitioner on behalf of the
study team. The consent form requests permission to examine
the patient’s medical records and to send an annual postal ques-
tionnaire (incorporating the modified Rankin scale, short form
36, hospital anxiety and depression scale, and the Barthel index
questionnaires); each patient can consent to either, both, or nei-
ther of these options. If there is no response to the first consent
pack from a patient the team sends postal reminders via the gen-
eral practitioner at three and six weeks after the initial approach.
Ethical approval for the study
The Multicentre Research Ethics Committee for Scotland
approved these recruitment methods (MREC/98/0/48) on the
basis of both the study team’s initial application for ethical
approval and subsequent clarification of the study’s methods.
The committee also accepted that every patient in the cohort
could be followed up prospectively each year until they died by
means of just annual questionnaires to their general practition-
ers and medical record surveillance rather than direct contact
with the patients, unless patients explicitly refused disclosure of
such information (in which case no further data would be gath-
ered). The committee approved these methods in view of the
public interest of avoiding consent bias.
Analysis of consent bias
This study includes all adults in Scotland in whom the common-
est subtype of intracranial vascular malformation, a brain
arteriovenous malformation, was first diagnosed in 1999-2002.
We reviewed the consensus reached by each patient’s general
practitioner and hospital consultant about whether the patient
could receive a consent pack, and the patient’s decision if sent a
consent pack within a year of the patient’s notification to the
study. We examined differences between patients who consented
(“consenters”) and those who did not (“non-consenters”) in their
demographic variables at recruitment and their outcome over a
median follow-up of 3.3 years (range 0-5.8 years).
Statistical methods
The variables we examined at the patients’ first presentation with
a brain arteriovenous malformation were age, sex, side of brain
affected, socioeconomic status (measured by deprivation
category of their residential postcode sector according to the
2001 census, obtained from the MRC Social and Public Health
Sciences Unit in Glasgow, www.msoc-mrc.gla.ac.uk), mode of
presentation, and dependence (assessed with the modified
Rankin scale). The variables examined during follow-up were
receipt of interventional treatment for the brain arteriovenous
malformation, survival (death from any cause), and morbidity
(modified Rankin scale at one year, time to first intracranial
haemorrhage, and time to first epileptic seizure for all patients;
and, for patients with epilepsy, time to being free of seizures for
one or two years).
The statistical tests used were analysis of variance (for mean
age), 2 test (for sex, modified Rankin scale ≥ 3 at presentation
and ≥ 3 or 3-5 at one year, receipt of interventional treatment
during follow-up), Fisher’s exact test (for side of brain affected,
mode of presentation), and 2 test for trend (for deprivation cat-
egory).
Results
In 1999-2002, 187 adults had a brain arteriovenous malforma-
tion diagnosed. Within the first year of their notification to the
study, the study team was discouraged from approaching 56
(30%) of these patients for consent by their general practitioner
or consultant. The reasons given were anxiety about diagnosis
(21 patients), dead at the time of trying to gain consent (15), and
cognitive impairment (9); no reason was given for six patients
and there was no reply to the questionnaire for five. Twenty
adults (11% of the whole cohort, 15% of those approached) did
not respond to the postal invitation to consent. None explicitly
withheld consent to the team examining his or her medical
records. The remaining 111 adults (59%) in the cohort gave their
explicit informed consent.
Comparison of consenters and non-consenters
At the time their brain arteriovenous malformations were
diagnosed, consenters were similar to non-consenters in their
mean age, sex distribution, and socioeconomic status (table).
However, the consenters differed significantly in the way they
presented, being less likely to present with haemorrhage and
more likely to present with seizure(s) than non-consenters.
Furthermore, consenters were significantly less likely to be dead
or dependent (modified Rankin scale ≥ 3) at presentation than
non-consenters.
At one year follow-up, consenters were significantly less likely
to be dead or dependent than non-consenters (table). This
difference was largely attributable to our inability to obtain con-
sent from adults who died soon after presentation (fig 1). The
difference in disability (modified Rankin scale 3-5) between sur-
viving consenters and non-consenters approached statistical sig-
nificance (table).
During the entire follow-up period, consenters and
non-consenters showed no significant difference in the probabil-
ity of intracranial haemorrhage (log rank = 0.97, P = 0.33). How-
ever, consenters did have a significantly shorter time to first
epileptic seizure after their initial presentation than non-
consenters (fig 2). There was no significant difference between

















Fig 1 Kaplan-Meier survival curve for death from all causes among 187 adults
with brain arteriovenous malformations by their consent to participate in an
observational study (consenters 2 deaths, non-consenters 12 deaths; log
rank=15.8, P=0.0001)
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with seizure(s) in their time to becoming seizure-free for one year
(31/37 v 11/12, P = 0.43) or two years (21/37 v 7/12, P = 0.56).
Consenters were more likely to receive interventional treatment
for their brain arteriovenous malformation after presentation
(table).
Effects of consent on results
These differences between consenters and non-consenters
affected the overall results of the study. After excluding the non-
consenters from our analyses, we found the consenters differed
significantly from the whole cohort in the proportion dead or
dependent at presentation and at one year (even after limiting
the analysis to just those who were alive at presentation) and in
their receipt of interventional treatment during follow-up (table).
Although consenters significantly differed from non-consenters
in their mode of presentation and dependence at one year, the
whole cohort did not differ from the consenters alone in these
analyses (table).
However, the important clinical finding of an association
between mode of initial presentation and risk of intracranial
haemorrhage during follow-up (before treatment) differed
depending on whether non-consenters were excluded from the
analysis. Initial presentation with intracranial haemorrhage con-
ferred a significantly higher risk of subsequent haemorrhage
than other modes of presentation when the whole cohort was
analysed (two bleeds among 95 adults who had not bled at pres-
entation, eight bleeds among 92 adults who had bled at presen-
tation; log rank = 8.4, P = 0.004), but this association disappeared
when the analysis was restricted to consenters (one bleed among
59 adults who had not bled at presentation, two bleeds among 52
adults who had bled at presentation; log rank = 1.3, P = 0.26).
Discussion
Our main finding is that in an observational disease register that
obtained explicit consent from almost two thirds of its cohort,
adults who consented were significantly different from those
who did not in both anticipated and unpredictable ways. This
kind of consent bias probably invalidates the findings of many
observational studies, as it would have our own if non-consenters
had been excluded.
We found that there were no significant differences in demo-
graphic variables between consenters and non-consenters, nor
was there a greater proportion of non-consenters harbouring a
brain arteriovenous malformation in the dominant (left) cerebral
hemisphere. However, consenters were significantly less likely to
have intracranial haemorrhage or to be dead or dependent at
presentation, reflecting the difficulty in gaining consent from
brain damaged patients (and, of course, from those who had died























Fig 2 Kaplan-Meier analysis of time to first seizure among 187 adults with
brain arteriovenous malformations by their consent to participate in an
observational study (consenters 42 events, non-consenters 13 events; log
rank=4.1, P=0.044)
Characteristics of 187 adult patients with brain arteriovenous malformations by their consent to participate in an observational study (values are numbers
(percentages, with 95% confidence intervals) of patients unless stated otherwise)
Characteristic All patients (n=187) Consenters (n=111) Non-consenters (n=76)
P value (consenters v
non-consenters)*
At presentation
Mean (SD) age (years) 45 (16) 44 (14) 47 (18) 0.18
Women 85 (46, 40 to 52) 49 (44, 37 to 52) 36 (47, 38 to 57) 0.66
Location of brain AVM:
Left 92 (49, 43 to 55) 57 (51, 44 to 59) 35 (46, 37 to 56) 0.58
Midline 7 (4, 2 to 7) 5 (5, 2 to 9) 2 (3, 1 to 8)
Right 88 (47, 41 to 53) 49 (44, 37 to 52) 39 (51, 42 to 61)
Deprivation category:
1 (most affluent) 4 (2, 1 to 5) 2 (2, 1 to 5) 2 (3, 1 to 8) 0.94
2 25 (13, 10 to 18) 16 (14, 10 to 21) 9 (12, 7 to 19)
3 44 (24, 19 to 29) 29 (26, 20 to 34) 15 (20, 13 to 28)
4 54 (29, 24 to 35) 27 (24, 18 to 32) 27 (36, 27 to 45)
5 29 (16, 12 to 20) 15 (14, 9 to 20) 14 (18, 12 to 27)
6 24 (13, 9 to 17) 18 (16, 11 to 23) 6 (8, 4 to 15)
7 (most deprived) 7 (3, 2 to 7) 4 (4, 2 to 8) 3 (3, 2 to 9)
Mode of presentation:
Haemorrhage 91 (49, 43 to 55) 46 (41, 34 to 49) 45 (59, 50 to 68) 0.009
Epilepsy 49 (26, 21 to 32) 37 (33, 26 to 41) 12 (16, 10 to 24)
Focal neurological deficit 8 (4, 2 to 7) 7 (6, 3 to 11) 1 (1, 0 to 6)
Incidental 39 (21, 16 to 26) 21 (20, 14 to 26) 18 (24, 17 to 33)
Modified Rankin scale ≥3 78 (42, 36 to 48) 34 (31, 24 to 38) 44 (58, 48 to 67) 0.0002
During follow-up
Received interventional treatment 126 (67, 62 to 73) 84 (76, 68 to 82) 42 (55, 46 to 64) 0.003
Modified Rankin scale ≥3 at one year 42 (23, 18 to 28) 13 (12, 8 to 18) 29 (38, 30 to 48) 0.00001
Modified Rankin scale 3-5 at one year† 26 (16, 12 to 21) 13 (12, 8 to 18) 13 (23, 15 to 34) 0.05
AVM=arteriovenous malformation. *See methods section for details of statistical tests used. †Denominator is the number alive at one year (111 consenters and 56 non-consenters).
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senters were significantly more likely to receive interventional
treatment, less likely to die, and more likely to have an epileptic
seizure. These differences affected the overall result of the study
if non-consenters were excluded from the final analysis.
We tested one clinically important prognostic variable and
found that it was vulnerable to consent bias. If the initial present-
ing feature of a brain arteriovenous malformation is intracranial
haemorrhage, it is generally accepted that there is a higher sub-
sequent risk of haemorrhage compared with other modes of
presentation.6 In clinical practice, this partly influences the deci-
sion to treat a brain arteriovenous malformation. In our study, we
confirmed this association when the whole cohort was analysed,
but the association disappeared when only consenters were ana-
lysed.
Our study has benefited from having a large, population
based cohort with outcome data on both consenters and
non-consenters. Because our disease register started when data
privacy legislation and guidance were changing dramatically in
the UK, a reappraisal of our methods by the Multicentre
Research Ethics Committee for Scotland was necessary. Our
clear demonstration of consent bias has been possible because
the committee recognised the support for medical research
given by section 33 of the Data Protection Act, the committee
also endorsed our hypotheses about consent bias, and because
Scotland is not subject to the Health and Social Care Act.
Our results show how the modern era of data privacy could
seriously prejudice the findings of observational research.
Although we studied a specific disease, brain arteriovenous mal-
formation, it provides a good example of the difficulties of
obtaining consent from a group of people with considerable
physical and psychological morbidity. Such serious illness
requires effective treatment or prevention, which must be
improved by unbiased research, which in turn must encompass
those patients with adverse outcomes (from whom it is more dif-
ficult to obtain consent).
Comparison with other studies
The existing literature on consent bias has primarily focused on
large health surveys that involve data collection either by post or
by interview in person. These studies have generally found con-
senters or responders to be more likely to be young, male,
healthier, non-smokers, better educated, and of higher socioeco-
nomic status.
In medical records research in Rochester, Minnesota, to
which 79% of adults had given consent, Jacobsen et al found that
adults were less likely to permit researchers to study their medi-
cal records if they were female, younger than 60, living close to
the Mayo Clinic, and had a sensitive diagnosis (such as mood dis-
order).7 More recently, in observational research involving inter-
view and medical record review, the organisers of the Registry of
the Canadian Stroke Network managed to obtain consent from
only 39% of patients, and 51% when trained nurses sought con-
sent: they also found that inpatient mortality was much lower for
the patients who gave written informed consent than for those
who did not.4
The proportion of patients giving consent in our study (59%)
and our methods straddle these two studies; our findings concur
with those of the stroke registry, yet our consenters did not show
the demographic differences observed in the Mayo Clinic medi-
cal records study or in the health survey literature. Although
consent bias is likely to be affected by the nature of the research
and the disease group being studied, it does not seem to be
wholly predictable either in direction or size.
Conclusions and recommendations
Several unanswered questions remain. Individuals who do not
respond to invitations for consent pose a dilemma. If explicit
consent is desired non-responders might be deemed implicit
non-consenters, as they were in our study. Sometimes consent is
implied in environments where public information about data
privacy is displayed, and explicit refusals are acted on, in which
case non-responders are regarded as implicit consenters.
Furthermore, individuals who are deemed unsuitable by their
doctors to be approached for consent (constituting 30% of our
cohort) are necessarily regarded as proxy non-consenters, but is
it not paternalistic to deny patients or their relatives the option of
consenting to participate in research into their own disease?
Further research should be directed towards exploring
consent bias in other disease groups and in other research
designs to see if the bias is pervasive and remains unpredictable.
If so, this would strengthen the argument for complete and rep-
resentative data collection for observational and non-intrusive
epidemiological research, as is currently the case for medical
audit (which does not require consent).
Patients, the public, and professional organisations must con-
sider the implications of blanket requirements for consent from
each and every patient, before epidemiology and health services
research are regarded as too biased to rely on.
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What is already known on this subject
Informed consent is desirable for the use of medical data
from which patients can be identified in observational
research
Many regulations demand that patients who do not or
cannot consent are excluded
Participants in health surveys tend to be more likely to be
young, male, healthier, non-smokers, better educated, and of
higher socioeconomic status
What this study adds
In an observational disease register, adults who consented
were both predictably and unpredictably different from
those who did not consent
A blanket requirement for consent from every patient in
observational research can bias studies’ findings
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